Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioCardia, Inc. (NASDAQ: BCDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary disease, BioCardia uses these filings to report on financial results, governance matters, clinical and regulatory milestones, and capital markets activity.
Here you can review current reports on Form 8-K, which BioCardia uses to announce material events such as quarterly financial results, progress in its CardiAMP and CardiALLO clinical programs, enrollment updates in the CardiAMP HF II Phase 3 trial, consultations with Japan’s PMDA, leadership and board changes, and notices related to Nasdaq listing compliance. These filings often incorporate or reference press releases that detail developments in the company’s investigational therapies and enabling technologies like the Helix delivery system and Morph vascular navigation platform.
Investors can also consult proxy materials such as the definitive proxy statement on Schedule DEF 14A, which outlines proposals for director elections, amendments to the equity incentive plan, auditor ratification, and advisory votes on executive compensation, as well as information on board structure and corporate governance. Periodic reports on Forms 10-K and 10-Q, referenced in company communications, provide broader context on risk factors, financial condition, and the status of clinical programs.
Stock Titan enhances these documents with AI-powered summaries that highlight key points, helping readers quickly understand the significance of lengthy filings, including complex sections on clinical trial status, equity financings, and listing compliance. Real-time updates from EDGAR, along with structured access to items such as results of operations, other events, and shareholder meeting notices, make this BCDA filings page a focused resource for analyzing BioCardia’s regulatory and corporate disclosures.
BioCardia, Inc. is registering up to 2,800,000 shares of common stock, up to 2,800,000 pre-funded warrants, up to 2,800,000 common warrants, and the shares of common stock issuable upon exercise of those warrants in a best efforts public offering. Each share or pre-funded warrant will be sold together with one common warrant, at an assumed combined public offering price of $2.27. The company expects net proceeds of about $5.3 million if all securities are sold, and estimates that, with current quarterly cash use of roughly $1.6 million, this funding would support operations into the second quarter of 2026.
BioCardia is a clinical-stage developer of bone marrow–derived cell and cell‑derived therapies for heart failure, chronic myocardial ischemia, and acute respiratory distress syndrome. The company is currently not in compliance with Nasdaq’s $2.5 million minimum stockholders’ equity rule and has been granted until September 29, 2025 to regain compliance. The offering is highly dilutive, carries no minimum raise or escrow, and involves speculative short‑dated warrants whose value depends on future stock price and stockholder approval in certain cases.